Markets:

Overview

News

Currencies

International

Treasuries

Glaukos Corporation Common Stock (NY:GKOS)

126.34 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EDT, Jun 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Glaukos Corporation Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Glaukos Stock: A Deep Dive Into Analyst Perspectives (12 Ratings) ↗

August 01, 2024

Via Benzinga

Meta To Rally Around 35%? Here Are 10 Top Analyst Forecasts For Thursday ↗

August 01, 2024

Via Benzinga

GKOS Stock Earnings: Glaukos Misses EPS, Beats Revenue for Q2 2024 ↗

July 31, 2024

GKOS stock results show that Glaukos missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

Via InvestorPlace

7 Leading MedTech Stocks for Next-Gen Health Solutions ↗

July 31, 2024

With healthcare innovations promising to deliver groundbreaking solutions, these MedTech stocks should be on your radar.

Via InvestorPlace

10 Analysts Have This To Say About Glaukos ↗

July 10, 2024

Via Benzinga

This Visa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday ↗

July 10, 2024

Via Benzinga

Deep Dive Into Glaukos Stock: Analyst Perspectives (12 Ratings) ↗

May 22, 2024

Via Benzinga

Analyst Ratings For Glaukos ↗

April 08, 2024

Via Benzinga

5 Analysts Have This To Say About Glaukos ↗

March 22, 2024

Via Benzinga

Eye Disease-Focused Glaukos' 'Investor Interest Should Continue To Gain Momentum:' Analyst ↗

May 02, 2024

Glaukos reports Q1 adjusted EPS loss, sales beat estimates. Strong guidance for 2024 with positive analyst sentiment, driving stock up 6.22%.

Via Benzinga

Topics Earnings

C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursday ↗

May 02, 2024

Via Benzinga

GKOS Stock Earnings: Glaukos Misses EPS, Beats Revenue for Q1 2024 ↗

May 01, 2024

GKOS stock results show that Glaukos missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

Via InvestorPlace

Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday ↗

April 03, 2024

U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday.

Via Benzinga

Topics Stocks

Glaukos: Q4 Earnings Insights ↗

February 21, 2024

Via Benzinga

Earnings Scheduled For February 21, 2024 ↗

February 21, 2024

Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million.

Via Benzinga

Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday ↗

February 22, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Analyst Ratings For Glaukos ↗

February 16, 2024

Via Benzinga

Glaukos' Newly Approved Glaucoma Treatment Is The 'Biggest Driver To Watch': Analyst ↗

December 21, 2023

Shares of Glaukos Corp (NYSE: GKOS) continued to climb in early trading on Thursday, after the company’s iDose TR (travoprost intracameral implant) received U.S.

Via Benzinga

Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Thursday ↗

December 21, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Unveiling 7 Analyst Insights On Glaukos ↗

December 21, 2023

Via Benzinga

Analyst Ratings for Glaukos ↗

November 28, 2023

Via Benzinga

4 Analysts Have This to Say About Glaukos ↗

November 08, 2023

Via Benzinga

8 Analysts Have This to Say About Glaukos ↗

September 26, 2023

Via Benzinga

Glaukos's Earnings Outlook ↗

August 01, 2023

Via Benzinga

iDoseTR Approval Sets Stage for Glaukos' Game-Changing Product, Surpassing Market Expectations, Says Analyst ↗

December 15, 2023

Thursday, the FDA approved Glaukos Corporation's (NYSE: GKOS) marketing application for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog...

Via Benzinga

Dow Extends Rally As Treasury Yields Tank ↗

December 14, 2023

The Dow Jones Industrial Average is charging full speed ahead, up 78 points this afternoon after yesterday closing at record highs, on the heels of the Federal Reserve's rate decision.

Via Talk Markets

Topics Economy Stocks

FDA Approves Glaukos' Eye Implant To Treat Eye Pressure In Glaucoma Patients ↗

December 14, 2023

The FDA approved Glaukos Corporation's (NYSE: GKOS) marketing application for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for...

Via Benzinga

Analyst Ratings for Glaukos ↗

July 31, 2023

Via Benzinga

Glaukos Poised To Surpass Expectations And Raise Outlook In Q2 FY23, Fueled By iStent And iAccess Launches: Analyst ↗

July 19, 2023

Needham expects Glaukos Corp (NYSE: GKOS) to surpass expectations and raise outlook in Q2 FY23, fueled by rebounding iStent inject volumes post-2022 reimbursement-driven declines. An additional upside...

Via Benzinga

These 2 Soaring Stocks Finished the Week Strong ↗

July 14, 2023

Wall Street coasted into the close on Friday but still had a good week.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.